Table 2.

Clinicopathologic significance of XRCC1 expression in PD-L1+ (TILs) and PD-L1 breast cancers

PD-L1 (TILs) and XRCC1 expression
XRCC1/PD-L1XRCC1+/PD-L1XRCC1/PD-L1+XRCC1+/PD-L1+PPadj
(A) Pathologic parameters
Tumor size
 <1 cm4 (7.4%)21 (38.9%)6 (11.1%)23 (42.6%)0.0440.0484
 >1–2 cm25 (7.3%)160 (46.5%)23 (6.7%)136 (39.5%)
 >2–5 cm23 (8.4%)89 (32.5%)37 (13.5%)125 (45.6%)
 >5 cm1 (9.1%)3 (27.3%)1 (9.1%)6 (54.5%)
Tumor stage
 131 (7.8%)172 (43.1%)32 (8.0%)164 (41.1%)0.0750.825
 220 (9.1%)75 (34.1%)29 (13.2%)96 (43.6%)
 31 (1.5%)27 (40.9%)6 (9.1%)32 (48.5%)
Tumor grade
 G17 (7.0%)51 (51%)4 (4%)38 (38%)1.57 × 10−12<0.00001
 G212 (5.3%)125 (55.6%)6 (2.7%)82 (36.4%)
 G334 (9.5%)98 (27.3%)57 (15.9%)170 (47.4%)
NPI
 ≤3.410 (5.4%)106 (57.6%)4 (2.2%)64 (34.8%)3.8 × 10−8<0.00001
 >3.441 (8.8%)159 (34.3%)59 (12.7%)205 (44.2%)
Mitotic index
 M1 (low; mitoses < 10)12 (5.5%)112 (51.6%)8 (3.7%)85 (39.2%)4.1 × 10−8<0.00001
 M2 (medium; mitoses 10–18)13 (10.1%)57 (44.2%)7 (5.4%)52 (40.3%)
 M3 (high; mitosis >18)28 (8.7%)94 (29.1%)52 (16.1%)149 (46.1%)
Tubule formation
 1 (>75% definite tubule)3 (8.6%)17 (48.6%)1 (2.9%)14 (40%)0.0210.0257
 2 (10%-75% definite tubule)13 (6.1%)102 (47.9%)16 (7.5%)82 (38.5%)
 3 (<10% definite tubule)37 (8.8%)144 (34.2%)50 (11.9%)190 (45.1%)
Pleomorphism
 1 (Small-regular uniform)1 (10.0%)4 (40.0%)0 (0%)5 (50.0%)8.5 × 10−9<0.00001
 2 (Moderate variation)18 (7.2%)136 (54.2%)8 (3.2%)89 (35.5%)
 3 (Marked variation)34 (8.4%)123 (30.2%)59 (14.5%)191 (46.9%)
Tumor type
 IDC-NST33 (7.8%)132 (31.4%)51 (12.1%)205 (48.7%)1.9 × 10−8<0.00001
 Tubular9 (7.4%)69 (56.6%)7 (5.7%)37 (30.3%)
 Medullary3 (15.8%)2 (10.5%)6 (31.6%)8 (42.1%)
 ILC3 (4.7%)39 (60.9%)1 (1.6%)21 (32.8%)
 Others1 (20.0%)2 (40.0%)0 (0%)2 (40.0%)
 Mixed NST & lobular/special type4 (10.0%)24 (60.0%)2 (5.0%)10 (25.0%)
Her2 overexpression
 No44 (7.5%)248 (42.2%)55 (9.4%)241 (41.0%)0.010.0138
 Yes10 (11.0%)22 (24.2%)9 (9.9%)50 (54.9%)
ER status
 ER19 (10.5%)34 (18.8%)35 (19.3%)93 (51.4%)2.4 × 10−12<0.00001
 ER+31 (6.4%)232 (47.5%)31 (6.4%)194 (39.8%)
PR
 Negative29 (10.7%)78 (28.7%)43 (15.8%)122 (44.9%)4.8 × 10−8<0.00001
 Positive22 (5.7%)185 (47.7%)22 (5.7%)159 (41.0%)